Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

500
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
500
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

502
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
502
Censoring Survival Data01:09

Censoring Survival Data

461
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
461
Survival Tree01:19

Survival Tree

337
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
337
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

327
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
327
Hazard Ratio01:12

Hazard Ratio

487
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
487

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.

Histopathology·2026
Same author

Explainable machine learning in healthcare: methods, interpretation, and applications for clinical research.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.

Blood advances·2025
Same author

Biological Mechanisms for Allen's Rule: DNA Methylation as Mediator of the Association Between In Utero Exposure to Environmental Heat and Tibial Growth in Childhood.

American journal of human biology : the official journal of the Human Biology Council·2025
Same author

Creating a Proxy for Baseline Eastern Cooperative Oncology Group Performance Status in Electronic Health Records for Comparative Effectiveness Research in Advanced Non-Small Cell Lung Cancer.

JCO clinical cancer informatics·2025
Same author

A Bayesian high-dimensional mediation analysis for multilevel genome-wide epigenetic data.

Journal of applied statistics·2025

Related Experiment Video

Updated: Dec 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.

Duy Ngo1,2, Richard Baumgartner1, Shahrul Mt-Isa3,4

  • 1Merck & Co., Inc., Kenilworth, NJ, United States of America.

Plos One
|February 27, 2020
PubMed
Summary

This study introduces a Bayesian credible subgroups approach to identify patient subgroups benefiting from specific treatments using time-to-event data. The method aids personalized medicine by estimating treatment effects more accurately.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Related Experiment Videos

Last Updated: Dec 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Personalized Medicine

Background:

  • Patient responses to pharmacotherapy vary, driving the need for personalized medicine.
  • Existing methods for time-to-event data often overlook subgroup multiplicity and focus solely on treatment-by-covariate interactions.
  • Identifying specific patient subgroups with differential treatment effects is crucial for effective drug development and clinical practice.

Purpose of the Study:

  • To introduce a novel Bayesian credible subgroups approach for analyzing time-to-event endpoints.
  • To provide a robust method for identifying patient subgroups that exhibit differential treatment effects.
  • To estimate personalized treatment effects using hazard ratios and restricted mean survival time.

Main Methods:

  • Development of the Bayesian credible subgroups approach for time-to-event data.
  • The method defines two bounding subgroups: one likely contained within the true benefiting subgroup and one likely containing it.
  • Application to a prostate carcinoma case study and a simulated large clinical dataset.

Main Results:

  • The Bayesian credible subgroups approach successfully identified potential benefiting subgroups in both the case study and simulated data.
  • The method provides a more nuanced understanding of treatment effects within specific patient populations.
  • Estimated personalized treatment effects using hazard ratios and restricted mean survival time.

Conclusions:

  • The Bayesian credible subgroups approach offers a valuable tool for personalized medicine, enhancing the identification of treatment-benefiting subgroups.
  • This method addresses limitations of existing approaches by considering multiplicity and providing interpretable subgroup estimates.
  • Further application in clinical trials can lead to more targeted and effective therapeutic strategies.